CytoDyn remains under FDA clinical hold; seeks authorized share increase for viability

CytoDyn Inc.

FDA partial clinical hold still unresolved; comprehensive resubmission made, outcome pending.
Workforce reductions implemented; cash burn rate and operating expenses cut to conserve resources.
Amarex arbitration final hearing scheduled for August 12, 2024; Sidley Austin LLP retained.
Developed MASH clinical trial protocol and AI partnership for longer-acting therapeutic.
Shareholders asked to approve increase in authorized common shares at Nov 9 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.